126 related articles for article (PubMed ID: 25118216)
1. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
Li X; Iida M; Tada M; Watari A; Kawahigashi Y; Kimura Y; Yamashita T; Ishii-Watabe A; Uno T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):206-13. PubMed ID: 25118216
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2.
Hashimoto Y; Hata T; Tada M; Iida M; Watari A; Okada Y; Doi T; Kuniyasu H; Yagi K; Kondoh M
Eur J Pharm Sci; 2018 May; 117():161-167. PubMed ID: 29448044
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
[TBL] [Abstract][Full Text] [Related]
4. Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.
Yang H; Park H; Lee YJ; Choi JY; Kim T; Rajasekaran N; Lee S; Song K; Hong S; Choi JS; Shim H; Kim YD; Hwang S; Choi YL; Shin YK
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31905631
[TBL] [Abstract][Full Text] [Related]
5. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer.
Kuwada M; Chihara Y; Luo Y; Li X; Nishiguchi Y; Fujiwara R; Sasaki T; Fujii K; Ohmori H; Fujimoto K; Kondoh M; Kuniyasu H
Cancer Lett; 2015 Dec; 369(1):212-21. PubMed ID: 26342407
[TBL] [Abstract][Full Text] [Related]
6. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
9. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
Hashimoto Y; Kawahigashi Y; Hata T; Li X; Watari A; Tada M; Ishii-Watabe A; Okada Y; Doi T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Pharmacol Res Perspect; 2016 Oct; 4(5):e00266. PubMed ID: 27713828
[TBL] [Abstract][Full Text] [Related]
11. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
13. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
16. Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines.
Hammer SC; Nagel S; Junginger J; Hewicker-Trautwein M; Wagner S; Heisterkamp A; Ngezahayo A; Nolte I; Murua Escobar H
Neoplasma; 2016; 63(2):231-8. PubMed ID: 26774145
[TBL] [Abstract][Full Text] [Related]
17. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
[TBL] [Abstract][Full Text] [Related]
18. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
[TBL] [Abstract][Full Text] [Related]
19. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
20. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]